Biodesign for the Ages: Redesigning R&D
Several factors contribute to the long runway needed – 10 years or more – for biotech and biomed innovations to rise to the market. They include regulations, global competitiveness, research and development and the decline in venture capital funding since the height of the pandemic. But can the emerging process of biodesign speed up R&D, thereby accelerating startup growth? Should design play a bigger part in companies’ R&D? We CONNECTED with Sheng-Hung Lee, a researcher at MIT AgeLab, and Jowy Tani, CEO of the Taipei Medical University Biome Accelerator, to understand how biodesign can be a game-changer for innovation in biotech, biomed and other health care fields.
